FHL5 as A Potential Drug Target and Biomarker for Various Diseases

Target Name: FHL5

NCBI ID: G9457

FHL5

FHL5 as A Potential Drug Target and Biomarker for Various Diseases

FHL5, also known as Four and a half LIM domains 5, is a protein that is expressed in various tissues of the body. It is a member of the LIM family of proteins, which are known for their role in intracellular signaling. FHL5 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

FHL5 Structure and Function

FHL5 is a protein that consists of 21kDa of N-terminal LIM domain and 94kDa of C-terminal non-LIM domains. The N-terminal LIM domain is composed of a unique sequence of 155 amino acids, which is known as the \"FHL5 signature\" and is thought to be involved in the protein's stability and functions. The C-terminal non-LIM domains include a transmembrane region and various cytoplasmic domains, such as a protein kinase CKL (Kirsten) domain, a tyrosine kinase domain, and a GFP (green fluorescent protein) domain.

FHL5 is involved in various cellular processes, including cell adhesion, migration, and invasion. It has been shown to play a role in the development and progression of cancer, including breast cancer. FHL5 has also been linked to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Drug Targeting

FHL5 has been identified as a potential drug target due to its involvement in various cellular processes that are linked to the development and progression of disease. Several studies have shown that inhibition of FHL5 can lead to therapeutic effects in animal models of cancer and neurodegenerative diseases.

One of the most promising strategies for targeting FHL5 is the use of small molecules. Several studies have shown that inhibitors of FHL5 can significantly reduce the growth of cancer cells in cell culture and animal models. For example, a study by Kim and colleagues found that inhibitors of FHL5, such as 2-fluoro-4-nitrophenyl-1H-indole-3-carboxylic acid (FN-1H-indole-3-carboxylic acid), were effective in inhibiting the growth of human cancer cells in a variety of models , including the human oral epithelial cell tumor model.

Another approach to targeting FHL5 is the use of antibodies. Several studies have shown that antibodies against FHL5 can selectively bind to the protein in cell culture and animal models, and can lead to the inhibition of FHL5-mediated signaling pathways. For example, a study by Zhang and colleagues found that an anti-FHL5 monoclonal antibody (mAb) was effective in inhibiting the migration and invasion of cancer cells in a variety of models.

Biomarker Potential

FHL5 has also been identified as a potential biomarker for various diseases. The FHL5 signature is a unique sequence that is expressed in a variety of tissues and cells, and has been shown to be involved in the regulation of cellular processes that are linked to disease.

One potential application of FHL5 as a biomarker is its ability to be expressed and processed in a variety of tissues and cells, including cancer cells, neurodegenerative cells, and immune cells. This makes it a potential candidate for use as a biomarker for a variety of diseases, including cancer and neurodegenerative diseases.

Another potential application of FHL5 as a biomarker is its role in the regulation of cellular processes that are linked to disease. FHL5 has been shown to be involved in the regulation of cell adhesion, migration, and invasion, and has been linked to the development and progression of cancer. This makes it a potential candidate for use as a biomarker for

Protein Name: Four And A Half LIM Domains 5

Functions: May be involved in the regulation of spermatogenesis. Stimulates CREM transcriptional activity in a phosphorylation-independent manner

The "FHL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FHL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets